These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21739761)

  • 1. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 3. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defending substantial equivalence: an argument for the continuing validity of the 510(k) premarket notification process.
    Flaherty JM
    Food Drug Law J; 2008; 63(4):901-27. PubMed ID: 19601388
    [No Abstract]   [Full Text] [Related]  

  • 5. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 6. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Express preemption and premarket approval under the Medical Device Amendments.
    Scandaglia GJ; Tully TL
    Food Drug Law J; 2004; 59(2):245-64. PubMed ID: 15318395
    [No Abstract]   [Full Text] [Related]  

  • 8. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 10. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: medical devices. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-35. PubMed ID: 23297445
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical devices; exemption from premarket notification and reserved devices; class I. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(10):2296-323. PubMed ID: 11010655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 14. Left to their own devices: breakdowns in United States medical device premarket review.
    Hines JZ; Lurie P; Yu E; Wolfe S
    PLoS Med; 2010 Jul; 7(7):e1000280. PubMed ID: 20634922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The medical device safety act of 2009: clarifying preemption.
    Turcott RG; Ashley EA
    Am J Ther; 2009; 16(6):471-4. PubMed ID: 19940607
    [No Abstract]   [Full Text] [Related]  

  • 16. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical devices; exemption from premarket notification requirements; class I devices; technical amendment. Final rule; technical amendment.
    Food and Drug Administration. HHS
    Fed Regist; 2001 Jul; 66(143):38786-819. PubMed ID: 11725800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical devices; exemptions from premarket notification and reserved devices; class I--FDA. Notice.
    Fed Regist; 1998 Feb; 63(21):5387-93. PubMed ID: 10177333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.